Reasons for discontinuing clozapine: a cohort study of patients commencing treatment by Legge, Sophie et al.
Schizophrenia Research 174 (2016) 113–119
Contents lists available at ScienceDirect
Schizophrenia Research
j ourna l homepage: www.e lsev ie r .com/ locate /schresReasons for discontinuing clozapine: A cohort study of patients
commencing treatmentSophie E. Legge a, Marian Hamshere a, Richard D. Hayes b, Johnny Downs b, Michael C. O'Donovan a,
Michael J. Owen a, James T.R. Walters a,⁎,1, James H. MacCabe b,c,1
a Division of Psychological Medicine and Clinical Neurosciences, MRC Centre for Neuropsychiatric Genetics and Genomics, School of Medicine, Cardiff University, Cardiff, UK
b Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, UK
c Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, UK⁎ Corresponding author at: Division of Psycholo
Neurosciences, School of Medicine, Cardiff University,
Road, Cathays, Cardiff CF24 4HQ, UK.
E-mail address:WaltersJT@Cardiff.ac.uk (J.T.R. Walters
1 Joint last authors.
http://dx.doi.org/10.1016/j.schres.2016.05.002
0920-9964/© 2016 The Authors. Published by Elsevier B.Va b s t r a c ta r t i c l e i n f oArticle history:
Received 29 January 2016
Received in revised form 3 May 2016
Accepted 4 May 2016
Available online 19 May 2016Background: Clozapine is uniquely effective in the management of treatment-resistant schizophrenia (TRS).
However, a substantial proportion of patients discontinue treatment and this carries a poor prognosis.
Methods: We investigated the risk factors, reasons and timing of clozapine discontinuation in a two-year
retrospective cohort study of 316 patients with TRS receiving their ﬁrst course of clozapine. Reasons for discon-
tinuation of clozapine and duration of treatment were obtained from case notes and Cox regression was
employed to test the association of baseline clinical factors with clozapine discontinuation.
Results:A total of 142 (45%) patients discontinued clozapinewithin two years. By studying the reasons for discon-
tinuations due to a patient decision, we found that adverse drug reactions (ADRs) accounted for over half of clo-
zapine discontinuations. Sedationwas themost commonADR cited as a reason for discontinuation and the risk of
discontinuation due to ADRs was highest in the ﬁrst few months of clozapine treatment. High levels of depriva-
tion in the neighbourhood where the patient lived were associated with increased risk of clozapine discontinu-
ation (HR = 2.12, 95% CI 1.30–3.47).
Conclusions: Living in a deprived neighbourhoodwas strongly associatedwith clozapine discontinuation. Clinical
management to reduce the burden of ADRs in the ﬁrst few months of treatment may have a signiﬁcant impact
and help more patients experience the beneﬁts of clozapine treatment.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Cessation1. Background
The superior efﬁcacy of clozapine has been consistently demonstrat-
ed for those with treatment-resistant schizophrenia (TRS) (Kane et al.,
1988; Leucht et al., 2009). Clozapine therapy has also been associated
with decreased rates of mortality (Hayes et al., 2015), suicide (Meltzer
et al., 2003; Tiihonen et al., 2009) and aggression (Chengappa et al.,
2002). However, approximately 40% of patients will discontinue cloza-
pine treatment within 24 months of initiation (Ciapparelli et al., 2000;
Davis et al., 2014; Whiskey et al., 2003), and this is often followed by a
rapid deterioration (Seppala et al., 2005), increased rates of compulsory
treatment, re-hospitalisation, and poorer functioning (Atkinson et al.,
2007; Wheeler et al., 2009).gical Medicine and Clinical
Hadyn Ellis Building, Maindy
).
. This is an open access article underGiven the beneﬁts of clozapine treatment and the poor prognosis for
those who discontinue, efforts have been made to identify patients that
may be at increased risk of discontinuation and to understand the
causes. An older age at clozapine initiation, Black African/Caribbean eth-
nicity and substance abuse have been found to be associatedwith cloza-
pine discontinuation (Davis et al., 2014; Krivoy et al., 2011; Moeller
et al., 1995). The most common reasons for discontinuation identiﬁed
in previous studies were patient decision, non-adherence and adverse
drug reactions (Atkinson et al., 2007; Davis et al., 2014; Mustafa et al.,
2015; Pai and Vella, 2012; Taylor et al., 2009). Although patient decision
and non-adherence have been identiﬁed asmajor reasons for discontin-
uation of clozapine, there has been no exploration of reasons behind this
choice.
The majority of previous studies have not been conducted in pa-
tients receiving their ﬁrst trial of clozapine and thus the identiﬁed rea-
sons for discontinuing may have been biased by previous clozapine
trials. In the current study, we investigated the risk factors, reasons
and timing of clozapine discontinuation in a two-year retrospective co-
hort study of all patients starting their ﬁrst clozapine trial over a ﬁve-the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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(SLaM) NHS Foundation Trust.
2. Method
2.1. Setting
The study used data from the Clinical Records Interactive Search
(CRIS) system; a large, anonymised case register derived from
South London and Maudsley (SLaM) NHS Foundation Trust electron-
ic case records and fully described elsewhere (Fernandes et al., 2013;
Stewart et al., 2009). The CRIS system allows researchers to search
structured and free text ﬁelds. SLaM is the largest secondary mental
health care provider in Europe serving approximately 1.2 million
people from four London boroughs; Lambeth, Croydon, Lewisham
and Southwark.
2.2. Sample inclusion criteria
The cohort consisted of patients who had a lifetime ever ICD-10 pri-
mary diagnosis of a psychotic disorder (F20–F29, inclusive) and who
began their ﬁrst trial of clozapine between 1 January 2007 and 31 De-
cember 2011. This study periodwas selected because electronic recordsFig. 1. Process of sample identiﬁcation. The sample was initially extracted using a general arc
where a prescription of clozapinewas indicated. Patients were then selectedwhose ﬁrst clozapi
more than a single day, had a lifetime ever ICD-10 F20–F29 diagnosis, and aged 18 years or gr
patients that met these criteria were manually screened and study eligibility veriﬁed from caswere fully implemented during 2006 in SLaM and clozapine initiations
on or before 31 December 2011 permitted a two-year follow-up to the
time of data extraction (January 2014). Patients were aged 18–
65 years at the start of clozapine treatment and initiated clozapine
under standard secondarymental health care services, either as an inpa-
tient or outpatient. Patients who received tertiary care from SLAM na-
tional services were excluded because complete follow-up data were
not always available and they were not a representative sample.
The process of cohort identiﬁcation is detailed in Fig. 1. A natural lan-
guage processing application built using general architecture for text
engineering (GATE) identiﬁed 3242 patients, from approximately
230,000 plus represented in CRIS, who had any evidence of current or
previous clozapine use. The application used multiple data sources to
identify medication use including pharmacy dispensing events, struc-
tured medication ﬁeld, clinical correspondence and free text entries,
resulting in a high degree of sensitivity (Hayes et al., 2015).We then se-
lected patients who had (i) ﬁrst clozapine prescription between 1 No-
vember 2006 (extended due to discussion that precedes clozapine
initiation) and 31 December 2011, (ii) ICD-10 F20–F29 diagnosis, and
(iii) aged 18 years or over on 31 December 2011 and 65 years or less
on 1 January 2007. The data for the 799 patients whomet these criteria
were manually screened and study eligibility veriﬁed from their elec-
tronic clinical records.hitecture for text engineering (GATE) application, which detected a total of 3242 patients
ne entrywas between 1 November 2006 and 31December 2011, had entries that spanned
eater on 31 December 2011 and 65 years or less on 1 January 2007. The data for the 799
e notes.
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The timing and the reasons for clozapine discontinuation were
assessed in a case note review for all patients who stopped treatment
within 24 months of initiation. The date of clozapine initiation was de-
ﬁned as the date the patient took their ﬁrst dose of clozapine. The date
of discontinuation was deﬁned as the date the patient was last known
to take clozapine, where this was followed by at least three consecutive
months without clozapine treatment.
Reasons for discontinuation were obtained from descriptive case
notes when explicitly stated by the patient's clinical team. These were
categorised into mutually exclusive reasons consistent with the previ-
ous literature (Atkinson et al., 2007; Davis et al., 2014; Mustafa et al.,
2015; Pai andVella, 2012; Taylor et al., 2009). If thereweremultiple rea-
sons that spanned more than one category (of which there were only
ﬁve instances), themost likely primary reasonwas inferred after discus-
sion between ﬁrst and corresponding author (Consultant Psychiatrist).
Reasons for discontinuation were coded into categories of; (i) adverse
drug reaction (ADR) deﬁned as any unwanted or harmful reaction
attributed to clozapine including intolerable side effects, (ii) non-
adherence not otherwise speciﬁed deﬁned as the patient declining to
take medication, not attending for blood monitoring, or missing doses
without informing their clinical team and with no reason for doing so
stated (iii) inadequate response deﬁned as insufﬁcient improvement in
symptoms, (iv) blood monitoring deﬁned as a dislike of either blood
tests or burden of frequent clinic visits, (v) belief medication not required
deﬁned as a patient belief that clozapine would not help them or that
they did not need any medication, (vi) delusional belief held by the pa-
tient speciﬁcally regarding clozapine, (vii) anticipated non-adherence
deﬁned as pre-emptive discontinuation initiated by the clinical team
as it was believed the patient would become non-adherent upon dis-
charge from inpatient services, (viii) death, regardless of whether the
cause was attributed to clozapine, and (ix) any other reason. If a patient
discontinued due to non-adherence but cited a reason for doing so, they
were classiﬁed under the reason given. To investigate differences in pa-
tients that were non-adherent, discontinuations were further classiﬁed
as a clinician-led decision (deﬁned as a discontinuation that was led by
the clinical team, although in most cases this was a consensual decision
between the patient and clinical team) or a patient decision (discontinu-
ation due to non-adherence by declining to takemedication, not attend-
ing for blood monitoring, or missing doses without informing their
clinical team).
The speciﬁc ADR was recorded if it was stated to be the reason for
discontinuation. These were not classiﬁed into mutually exclusive
causes because in the majority of cases a number of ADRs were cited
per patient andwewanted to reﬂect the broad adverse effect proﬁle re-
sponsible for treatment discontinuation.
2.4. Exposure variables
Demographic details of age, gender,marital status, ethnicity, diagno-
sis, inpatient status and detention under theMentalHealthActwere ob-
tained from structured ﬁelds within CRIS. Age was deﬁned as the
patient's age at the date of clozapine initiation. Marital status was clas-
siﬁed into currently married/cohabiting and single. Self-reported ethnici-
ty was coded as Black African/Caribbean and other. The decision to
aggregate into these categories was based on Black African/Caribbean
ethnicity being the largest group within our sample, the relatively
small cell counts of other ethnic groups, and trends reported in previous
literature (Davis et al., 2014; Moeller et al., 1995). Diagnosis was classi-
ﬁed into schizophrenia (ICD-10 code: F20) and non-schizophrenia F21–
9 diagnosis (F21–F29, inclusive). The diagnosis closest in date to the
start of clozapine was selected.
Level of deprivation was calculated from the 2007 Index of Multiple
Deprivation (IMD) for England. The IMD is made up of seven individual
measures of deprivation (income, employment, health deprivation anddisability, education skills and training, barriers to housing and services,
crime, and living environment) and is an established score for investi-
gating social deprivation. The IMD score is calculated for geographical
areas, which are ranked from one (most deprived) to 32,482 (least de-
prived).Wearrived at cut-offs of deprivation ranks to give three roughly
equal groups: high (1–5500), intermediate (5501–10,000) and low
(10,001–32,482). The patient's home address closest to the start of the
study period (1st January 2007) was used, with a separate category
assigned to those who were homeless.
2.5. Analysis
We used a Kaplan-Meier survival curve to display the time to all-
cause clozapine discontinuation and reasons for discontinuation. Hav-
ing checked proportional hazard assumptions, a Cox regression was
employed tomodel the association between all-cause clozapine discon-
tinuation and gender, age, marital status, ethnicity, level of deprivation,
diagnosis, inpatient status and detention under the Mental Health Act.
Associations with all-cause discontinuation were assessed in a crude
univariate analysis, and also in models that had been fully adjusted for
all variables examined. Level of deprivation was entered into the
model as a categorical dummy variable. We tested the appropriateness
of entering age as a continuous variable with a likelihood ratio test. We
investigated interaction effects with age, gender and ethnicity for vari-
ables signiﬁcantly associated with all-cause discontinuation (P b 0.05).
Sensitivity analyses were conducted whereby (i) death was classiﬁed
as censored data rather than as a reason for all-cause discontinuation,
and (ii) only patients with a diagnosis of schizophrenia (ICD-10 F20)
were included. Competing-risks regression (Fine and Gray, 1999; Kim,
2007) was employed to model the impact of predictors on cause-
speciﬁc discontinuation, whilst taking into account the other causes,
ﬁrstly in a crude analysis and secondly, fully adjusted for all covariates
examined. The speciﬁc causes of discontinuation investigated were;
ADRs, non-ADRs (all reasons other than ADRs), clinician-led decision
and patient decision. All statistical analyses were performed using
STATA version 12 (StataCorp, 2011).
2.6. Ethical standards
Ethical approval for the use of CRIS as a research dataset was given
by Oxfordshire Research Ethics Committee C (08/H0606/71) and the
CRIS oversight committee granted permission for this study.
3. Results
3.1. Patient characteristics
A total of 316 patients were included in the study. Sample character-
istics are presented in Table 1. Themajority of the sample had a diagno-
sis of schizophrenia (n = 285) and the most common non-
schizophrenia diagnosis was schizoaffective disorder (n = 21). In the
other ethnicity category, 127 were White British, 17 Asian and 21 of
other ethnicity. The majority of the 162 (51.3%) patients who were
detained under theMental Health Act at the time of clozapine initiation
were under a section 3 (detention for treatment, n = 124) or sections
37–49 (forensic, n = 30).
3.2. Reasons for discontinuation
A total of 142 (45%) patients discontinued their ﬁrst trial of clozapine
within 24 months of initiation. Table 2 details the reasons for clozapine
discontinuation. In total, 65 discontinuations (20.6% of all those starting
clozapine)were from a clinician-led decision and 74 (23.4%)were from a
patient decision. Three patients (0.9%) died within the study period. The
majority of discontinuations from a clinician-led decision were due to
ADRs (n = 54). We were able to obtain reasons for 49 of the 74
Table 1
Sample characteristics and risk for clozapine discontinuation.Columns represent characteristics for total sample, those that discontinued and continued (reference group), hazard ratio
and P-value from crude and fully adjusted Cox regression. Data for all 316 patients was available for each variable other than level of deprivation, which was available for 310 patients.
Crude Fully adjusteda
Characteristic
Total sample
(n = 316)
n (%)
Discontinued
(n = 142)
n (%)
Continued
(n = 174)
n (%)
Hazard ratio
(95% CI) P-value
Hazard ratio
(95% CI) P-value
Male gender 205 (64.87) 89 (62.68) 116 (66.67) 0.86 (0.61–1.21) 0.381 0.77 (0.53–1.10) 0.155
Age at clozapine onset (years, SD) 36.23 (10.9) 36.11 (11.29) 36.33 (10.66) 1.00 (0.98–1.01) 0.717 0.99 (0.98–1.01) 0.423
Currently married or cohabiting 27 (8.54) 14 (9.86) 13 (7.47) 1.26 (0.73–2.19) 0.407 1.40 (0.76–2.57) 0.284
Black African/Caribbean ethnicity 151 (47.78) 81 (57.04) 70 (40.23) 1.55 (1.11–2.16) 0.010 1.26 (0.89–1.80) 0.194
Level of deprivation
Low 84 (26.58) 26 (18.31) 58 (33.33) Ref Ref
Intermediate 112 (35.44) 53 (37.32) 59 (33.91) 1.72 (1.08–2.75) 0.024 1.74 (1.06–2.83) 0.027
High 100 (31.65) 55 (38.73) 45 (25.86) 2.21 (1.38–3.52) 0.00091 2.12 (1.30–3.47) 0.0027
Homeless 14 (4.43) 6 (4.23) 8 (4.60) 1.44 (0.59–3.50) 0.419 1.51 (0.61–3.71) 0.373
Non-schizophrenia F21–9 diagnosis 31 (9.81) 14 (9.86) 17 (9.77) 1.01 (0.58–1.76) 0.966 0.82 (0.46–1.46) 0.497
Inpatient 262 (82.91) 115 (80.99) 147 (84.48) 0.84 (0.55–1.27) 0.401 0.66 (0.39–1.11) 0.119
Detained under Mental Health Act 162 (51.27) 81 (57.04) 81 (46.55) 1.32 (0.95–1.84) 0.104 1.34 (0.88–2.03) 0.168
Note: Follow-up period begins at start of clozapine treatment (from January 1, 2007 to December 31, 2011, inclusive) and ends with discontinuation, death or end of study period (24
months after treatment onset).
a Fully adjusted includes all variables.
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tients were classiﬁed as non-adherence NOS. ADRs were the most com-
mon reason for discontinuation from a patient decision (n = 26),
followed by a dislike of blood monitoring (n = 10). Combined, ADRs at-
tributed to clozapine were responsible for over half of the total discon-
tinuations (n= 80). Discontinuations due to blood monitoring (n= 11)
and an inadequate response (n= 8)weremore frequent for patient than
clinician-led discontinuations.3.3. Time to clozapine discontinuation
Fig. 2 displays a Kaplan-Meier survival curve for the time to all-cause
clozapine discontinuation and for overall reasons of ADRs, non-
adherence NOS, blood monitoring and inadequate response. Due to the
small number of observations, the timings of discontinuations due to
reasons of a belief medication is not required, delusional belief, anticipated
non-adherence, death and other were not displayed. Supplementary
Table 1 gives the timings for all combined reasons. A substantial propor-
tion of those who initiated clozapine discontinued within the ﬁrst few
months: 12.3% within one month, 20% within three months and 38%
within a year. The mean time to all-cause discontinuation was
5.9 months and the median 4.0 months (analysis restricted to those
that discontinued within 24 months). The risk of discontinuations due
to ADRs was highest in the ﬁrst three months of clozapine treatment
(Fig. 2). By contrast, the risk of discontinuation due to non-adherenceTable 2
Reasons for clozapine discontinuation. Columns represent discontinuations resulting
from a clinician-led decision, patient decision, and combined total reasons. Percentages re-
late to all patients starting clozapine (n = 316).
Reason for discontinuation
Clinician-led decision
n (%)
Patient decision
n (%)
Combined
n (%)
Adverse drug reaction 54 (17.1) 26 (8.2) 80 (25.3)
Non-adherence NOS – 25 (7.9) 25 (7.9)
Blood monitoring 1 (0.3) 10 (3.2) 11 (3.5)
Inadequate response 3 (0.9) 5 (1.6) 8 (2.5)
Belief medication not
required
0 (0.0) 4 (1.3) 4 (1.3)
Delusional belief 0 (0.0) 4 (1.3) 4 (1.3)
Anticipated non-adherence 2 (0.6) 0 (0.0) 2 (0.6)
Other 5 (1.6) 0 (0.0) 5 (1.6)
Death – – 3 (0.9)
Total 65 (20.6) 74 (23.4) 142 (44.9)NOS, blood monitoring and inadequate response were evenly distributed
across the study period.
In a comparison of all-cause clozapine discontinuation timings of cli-
nician-led and patient decisions (Supplementary Fig. 1, Supplementary
Table 2 and Supplementary Table 3), we observed that the risk in the
ﬁrst three months of treatment was higher for clinician-led than patient
discontinuations.
3.4. Adverse drug reactions
The 80 patientswhodiscontinued clozapine due toADRs cited a total
of 130 individual ADRs. Fig. 3 displays the proportion of discontinua-
tions due to ADRs that were from a clinician-led or patient decision (fre-
quencies listed in Supplementary Table 4). Overall, sedation (n = 28),
neutropenia (n=15) and tachycardia (n=13)were themost common
ADRs cited as a reason for discontinuation of clozapine. The most com-
mon ADRs cited for clinician-led discontinuations were neutropenia
(n = 15), sedation (n = 13), tachycardia (n = 12) and dizzinessFig. 2. Time to clozapine discontinuation. Kaplan-Meier survival curve demonstrating
proportion remaining on clozapine over initial 24 months of clozapine treatment. Blue
line represents all-cause discontinuation. Other lines represent discontinuations due to
adverse drug reactions (green), non-adherence not otherwise speciﬁed (grey), blood
monitoring (red) and inadequate response (orange).
Fig. 3. Adverse drug reactions (ADRs) cited as a reason for discontinuation of clozapine
for 80 patients (130 ADRs). ADRs are not exclusive and differentiated by whether the
discontinuation was a clinician-led decision (blue) or a patient decision (grey).
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from a patient decision was sedation (n = 15), followed by nausea
(n = 6), hypersalivation (n = 4) and weight gain (n = 4).3.5. Risk factors for discontinuation
Table 1 details the association of predictors with all-cause cloza-
pine discontinuation. In the fully adjusted model, intermediate (haz-
ard ratio (HR) = 1.74, 95% CI 1.06–2.83) and high neighbourhood
deprivation (HR = 2.12, 95% CI 1.30–3.47) were associated with in-
creased risk for all-cause clozapine discontinuation. Black African/
Caribbean ethnicity was associated with all-cause discontinuation
in the crude analysis (HR = 1.55, 95% CI 1.11–2.16) but the associa-
tion attenuated when fully adjusted (HR = 1.26, 95% CI 0.89–1.80).
Gender, age, marital status, diagnosis, inpatient status and detention
under the Mental Health Act were not associated with all-cause clo-
zapine discontinuation. No interaction effects were identiﬁed. There
were no differences in sensitivity analyses where death was not
classed as a cause of discontinuation (Supplementary Table 5). How-
ever, in a sensitivity analysis restricted to those with a schizophrenia
diagnosis, initiating clozapine as an inpatient was associated with a
reduced risk of discontinuation (HR = 0.53, 95% CI 0.31–0.90, Sup-
plementary Table 6).
Competing-risks regressions were used to investigate risk for cause-
speciﬁc discontinuations. The association of predictors with discontinu-
ations due to ADRs and non-ADRs are detailed in Supplementary Table 7.
There was a signiﬁcant association between level of deprivation and
non-ADR discontinuations, but this was no longer signiﬁcant in the
fully adjustedmodel. The association of predictors with discontinuation
due to a clinician-led decision or patient decision was also investigated
(Supplementary Table 8). High deprivation was signiﬁcantly associated
with patient decision discontinuations, in both the crude and fully ad-
justed models (HR = 2.17, 95% CI 1.11–4.24).4. Discussion
In a retrospective cohort study, we found that 45% of patients
discontinued their ﬁrst trial of clozapine within 24 months of initiation.
Adverse drug reactions (ADRs) were responsible for over half of
clozapine discontinuations and the risk of discontinuations due to
ADRs was highest in the ﬁrst few months of clozapine treatment.
Neighbourhood deprivation was associated with an increased risk of
clozapine discontinuation.4.1. Reasons for discontinuation
This is the ﬁrst study to examine in detail the reasons for discontin-
uations due to a patient decision and distinguish them from clinician-led
or joint decisions to discontinue. By studying these reasons, we found
that ADRs accounted for over half of clozapine discontinuations. Our re-
sults suggest that the role of ADRs has been underestimated as previous
studies have used a restricted number of categories for discontinuation
(i.e. patient choice and non-adherence), with no studies categorising the
underlying reasons (Davis et al., 2014; Krivoy et al., 2011;Mustafa et al.,
2015; Pai and Vella, 2012; Taylor et al., 2009). Our results are consistent
with studies that have shown a quarter to two thirds of non-adherence
to other antipsychotics was attributable to ADRs (Fenton et al., 1997;
Hudson et al., 2004).
Sedation was the most frequently cited adverse effect, accounting
for 20% of all discontinuations. Interestingly, over half of discontinua-
tions due to sedation were from a patient decision. This is an important
ﬁnding since sedation is usually transient and can almost always be
minimised by reducing the dose and/or titration rate of clozapine,
adjusting the timing of the dose or partial substitution with less sedat-
ing drugs such as aripiprazole (Nair and MacCabe, 2014). Around 10%
of patients who start clozapine are discontinuing for this reason; it is
likely many could remain on clozapine if this adverse effect was more
actively managed and monitored by the clinical team.
It has been suggested that many discontinuations due to other ADRs
could be avoided (Nielsen et al., 2013), although the appropriateness of
any given reason was not assessed in this study. Nonetheless, our ﬁnd-
ings suggest that prompt identiﬁcation and appropriatemanagement of
ADRs has the potential to improve continuation of clozapine treatment.
Consistent with earlier reports (Davis et al., 2014; Mustafa et al.,
2015; Pai and Vella, 2012; Taylor et al., 2009), discontinuation due pri-
marily to an inadequate response to clozapine was rare, occurring in
only 2.5% of patients. Given that non-response to clozapine has been es-
timated between 40 and 70% (Kane et al., 1988; Lieberman et al., 1994),
this result is unlikely to reﬂect the true rates of non-response to cloza-
pine but rather that non-response is seldom recorded as the primary
reason to discontinue treatment. A patient (or clinician) may be more
likely to tolerate an ADR and be willing to persevere with clozapine if
they are experiencing a good clinical response to clozapine, but might
instead discontinue clozapine, citing adverse effects, in the absence of
a clinical response. Nevertheless, the small percentage of patients who
discontinue primarily due to inadequate response is striking. It could
be driven partly by concern over risk of further relapse upon cessation
(Seppala et al., 2005) and partly by a lack of any other evidence-based
treatment options.
An interesting and novel insight was the observation that discontin-
uation of clozapine due to a dislike of blood monitoringwas reported in
3.5% of patients. This raises the question of whether rates would be
higher in all those eligible for clozapine, an important issue given that
low rates of clozapine prescription have been attributed to the burden
of blood monitoring (Nielsen et al., 2010). In this cohort of patients ini-
tiating clozapine, three patients died (2% of discontinuations) during
the follow-up period. This is in contrast with cross sectional studies of
clozapine discontinuation, which reported death as accounting for 13%
of clozapine discontinuations (Davis et al., 2014; Taylor et al., 2009).
4.2. Risk factors for discontinuation
As far aswe are aware, this is theﬁrst study to observe an association
between level of neighbourhood deprivation and risk of clozapine dis-
continuation. Furthermore, we found this result was driven by discon-
tinuations resulting from a patient decision. Previous studies have
reported mixed results regarding the relationship between socio-
economic status and non-adherence to medication (Kane et al., 2013),
although it is not measured in many studies. There is an established as-
sociation between markers of social derivation (including at the
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there is very limited further research exploring the nature and implica-
tions of this link (O'Donoghue et al., 2016). It is likely that social depri-
vation is a proxy marker for other factors that underlie discontinuation
and non-adherence and therefore, the next stage should be to identify
the causal factors that are acting in more deprived neighbourhoods
that explain the association. These causal factors may include both indi-
vidual level and wider health care related components. Individual level
characteristics of these patient groups that may increase risk for cloza-
pine discontinuation include comorbid substance abuse and chaotic so-
cial circumstances, which are associated with both neighbourhood
deprivation anddiscontinuation (Krivoy et al., 2011). Alternatively, clin-
ical teams supporting areas in high deprivationmay be under increased
pressure or have more limited resources. However, there is limited evi-
dence to suggest that patients with schizophrenia living in more de-
prived neighbourhoods have different prescribing experiences to
patients living in more afﬂuent areas (Martin et al., 2014).
Consistent with previous studies, we observed increased rates of all-
cause clozapine discontinuation in Black African/Caribbean patients
(Davis et al., 2014; Moeller et al., 1995); 54% of Black African/Caribbean
patients discontinued compared with 40% of non-Black African/Carib-
bean patients. However, this association attenuated and was not statis-
tically signiﬁcant after adjusting for other factors.We foundno evidence
to support previous ﬁndings that higher age at clozapine initiation in-
creased risk for discontinuation (Davis et al., 2014; Krivoy et al., 2011;
MacGillivray et al., 2003).
4.3. Study limitations
The primary limitation of this study is its retrospective nature, spe-
ciﬁcally that the quality of data available to determine reasons for dis-
continuation was limited to information entered into the electronic
clinical records system by the patient's clinical team. However, beneﬁts
of this study design are that the results are reﬂective of routine clinical
care and there was universal capture of patients commencing clozapine
in a deﬁned geographical area covering a population of 1.2 million peo-
ple, with consequently little or no selection bias. The fact that informed
consent was not required also eliminated the selection bias in favour of
higher functioning patients that bedevils research on psychosis. Recall
bias was minimised by the use of contemporaneous records and the
minimal missing data allowed us to determine the reasons for discon-
tinuation for all of the patients. Furthermore, CRIS incorporates routine-
ly collected data from multiple sources, such as pharmacy dispensing
information, to increase reliability. Although the use of IMD categories
is a widely accepted approach to measure neighbourhood deprivation,
it is possible that a postcode area may not be homogeneous and could
contain varying levels of deprivation.
4.4. Conclusions
Considering that clozapine is themost effective treatment for TRS, it
is important that avoidable discontinuation is minimised. By examining
the reasons for discontinuations due to a patient decisionwe found that
ADRs accounted for the majority of clozapine discontinuations. It is im-
portant that clinicians identify and treat ADRs attributed to clozapine,
particularly in the ﬁrst few months after treatment onset, before they
lead to discontinuation. Patients who live in an area of high deprivation
are at an increased risk of discontinuing clozapine and may need addi-
tional support to maintain engagement with treatment.
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